Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FCN-437c in HR+/HER2- Advanced Breast Cancer
NCT05439499Phase 3Unknown
- Sponsor
- Jinzhou Ahon Pharmaceutical Co., Ltd.
- Start
- Mar 2022
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing FCN-437c Arm with Placebo Arm (2 arms). Primary endpoint: Progression-Free Survival at 3 years. Status: unknown.
02
Drugs
ongiciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05439499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05439499.